Figure 6
Tumor treatment with BCG is partially dependent on a synergistic effect of endosomal TLRs and totally dependent on MyD88 signaling. Triple deficient animals TLR3/7/9−/− were used to evaluate the synergistic effect of endosomal TLRs and MyD88−/− deficient mice used to define the role of this adaptor molecule in tumor regression. Mice were submitted to the subcutaneous tumor model and BCG treatment. Tumor growth curves and the final volumes (day 22) are shown for TLR3/7/9−/− (A, B) and MyD88−/− (C, D). Data represents mean and standard deviation from the results of at least two independent experiments. C57BL/6 WT data represents the summary of control animals from all in vivo experiments comparing WT and KO mice. *Statistically significant compared to the respective untreated control, *P < 0.05, ****P ≤ 0.0001. #Statistically significant compared to BCG treated C57BL/6 WT, ####P ≤ 0.0001.
